86 related articles for article (PubMed ID: 25232917)
41. Evaluation of
Lotfi Garavand A; Mohammadi M; Mohammadzadeh S
Rep Biochem Mol Biol; 2020 Apr; 9(1):26-32. PubMed ID: 32821748
[TBL] [Abstract][Full Text] [Related]
42. Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer.
Lee JE; Lee SJ; Namkoong SE; Um SJ; Sull JW; Jee SH; You YK; Park JS
Int J Gynecol Cancer; 2004; 14(1):118-25. PubMed ID: 14764039
[TBL] [Abstract][Full Text] [Related]
43. The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.
Braunagel D; Schaich M; Kramer M; Dransfeld CL; Ehninger G; Mahlknecht U
Leuk Lymphoma; 2012 May; 53(5):952-7. PubMed ID: 22035418
[TBL] [Abstract][Full Text] [Related]
44. Associations of interleukin-10 gene polymorphisms with acute myeloid leukemia in human (Egypt).
Rashed R; Shafik RE; Shafik NF; Shafik HE
J Cancer Res Ther; 2018; 14(5):1083-1086. PubMed ID: 30197353
[TBL] [Abstract][Full Text] [Related]
45. Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population.
Lee MK; Cheong HS; Koh Y; Ahn KS; Yoon SS; Shin HD
Genet Test Mol Biomarkers; 2016 Nov; 20(11):696-701. PubMed ID: 27610459
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Value of a CYP2B6 Gene Polymorphism in Patients with Acute Myeloid Leukemia.
Alazhary NM; Shafik RE; Shafik HE; Kamel MM
Asian Pac J Cancer Prev; 2015; 16(11):4583-7. PubMed ID: 26107207
[TBL] [Abstract][Full Text] [Related]
47. Gene polymorphisms of p53-mediated apoptosis in chronic lymphocytic leukemia patients: features of distribution depending on radiation factor in anamnesis.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV
Probl Radiac Med Radiobiol; 2014 Sep; 19():223-30. PubMed ID: 25536560
[TBL] [Abstract][Full Text] [Related]
48. Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Rodríguez-Veiga R; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2018 Apr; 18(2):301-307. PubMed ID: 28485375
[TBL] [Abstract][Full Text] [Related]
49. DNA Repair Genes Polymorphisms: Impact on Acute Myeloid Leukemia Patients Outcome.
Aref S; El Menshawy N; Abou Zeid T; Gouda E; Abdel Aziz N
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3577-3585. PubMed ID: 36308385
[TBL] [Abstract][Full Text] [Related]
50. ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients.
Butrym A; Łacina P; Bogunia-Kubik K; Mazur G
Curr Probl Cancer; 2021 Oct; 45(5):100729. PubMed ID: 33714589
[TBL] [Abstract][Full Text] [Related]
51. Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma.
Lurje I; Czigany Z; Bednarsch J; Gaisa NT; Dahl E; Knüchel R; Miller H; Ulmer TF; Strnad P; Trautwein C; Tacke F; Neumann UP; Lurje G
Liver Cancer; 2022 Apr; 11(2):162-173. PubMed ID: 35634429
[TBL] [Abstract][Full Text] [Related]
52. Characterization of upregulated adhesion GPCRs in acute myeloid leukemia.
Yang J; Wu S; Alachkar H
Transl Res; 2019 Oct; 212():26-35. PubMed ID: 31153896
[TBL] [Abstract][Full Text] [Related]
53. Whole-genome sequencing: a step closer to personalized medicine.
Pasche B; Absher D
JAMA; 2011 Apr; 305(15):1596-7. PubMed ID: 21505140
[No Abstract] [Full Text] [Related]
54. Translating genetic questions into clinical answers in acute myeloid leukemia.
Vora S; Ellis N; Onel K
Leuk Res; 2009 Nov; 33(11):1448-9. PubMed ID: 19631381
[No Abstract] [Full Text] [Related]
55. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.
El-Danasouri NM; Ragab SH; Rasheed MA; Ali El Saadany Z; Abd El-Fattah SN
Ann Clin Lab Sci; 2014; 44(4):449-54. PubMed ID: 25361931
[TBL] [Abstract][Full Text] [Related]
56. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.
Grunwald MR; Tseng LH; Lin MT; Pratz KW; Eshleman JR; Levis MJ; Gocke CD
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1989-95. PubMed ID: 25240816
[TBL] [Abstract][Full Text] [Related]
57. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
Terwijn M; Zeijlemaker W; Kelder A; Rutten AP; Snel AN; Scholten WJ; Pabst T; Verhoef G; Löwenberg B; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
[TBL] [Abstract][Full Text] [Related]
58. CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia.
Hughes JM; Salvatori B; Giorgi FM; Bozzoni I; Fatica A
J Hematol Oncol; 2014 Sep; 7():69. PubMed ID: 25252716
[TBL] [Abstract][Full Text] [Related]
59. Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.
Zhou J; Chng WJ
World J Stem Cells; 2014 Sep; 6(4):473-84. PubMed ID: 25258669
[TBL] [Abstract][Full Text] [Related]
60. High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia.
Liu Y; Tang J; Wakamatsu P; Xue H; Chen J; Gaynon PS; Shen S; Sun W
Front Pediatr; 2014; 2():96. PubMed ID: 25250304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
